I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

What happenedShares of Akero Therapeutics (NASDAQ: AKRO) were down more than 70% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Find out why AKRO stock is a Buy.

Fintel reports that on August 4, 2025, TD Cowen initiated coverage of Akero Therapeutics (NasdaqGS:AKRO) with a Buy ...

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

In the last 3 months, 6 analysts have offered 12-month price targets for Akero Therapeutics. The company has an average price target of $62.67 with a high of $83.00 and a low of $33.00.

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.

Akero Therapeutics Inc has a consensus price target of $68.22 based on the ratings of 11 analysts. The high is $109 issued by UBS on January 31, 2025. The low is $38 issued by Evercore ISI Group ...

Akero Therapeutics’ experimental NASH drug, efruxifermin, met the main and secondary goals of Phase 2b clinical trial. The biotech will still need to show that the drug’s efficacy can hold up ...